Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Chroma Dermatology","sponsor":"DermBiont","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Chroma Dermatology

    Menu

    Chroma Dermatology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Chroma Dermatology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development

              Details:

              Acquisition of clinical-stage biotechnology company Chromaderm by DermBiont, will accelerate the development of Chromaderm’s drug candidate, ruboxistaurin (SM-030), topical formulation of the first and only targeted drug to treat skin hyperpigmentation.

              Lead Product(s): Ruboxistaurin

              Therapeutic Area: Dermatology Product Name: SM-030

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: DermBiont

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY